
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Zydus Lifesciences | USFDA | Depression

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Zydus Lifesciences Ltd on Monday said its US arm has received tentative approval from the US Food and Drug Administration to market generic Levomilnacipran extended-release capsules used to treat depression.
The tentative approval granted by the US Food and Drug Administration (USFDA) to Zydus Pharmaceuticals (USA) Inc is to market Levomilnacipran extended-release capsules of strengths 20 mg, 40 mg, 80 mg, and 120 mg, the company said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Moraiya in Ahmedabad, it added.
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults, Zydus Lifesciences said.
The capsules had annual sales of USD 85 million in the US, the company said citing IQVIA MAT September 2022 data.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Mon, January 16 2023. 14:38 IST
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more